Delamarre L - Search Results

1

Characterizing neoantigens for personalized cancer immunotherapy.

Capietto AH, Jhunjhunwala S, Delamarre L. Capietto AH, et al. Among authors: delamarre l. Curr Opin Immunol. 2017 Jun;46:58-65. doi: 10.1016/j.coi.2017.04.007. Epub 2017 May 4. Curr Opin Immunol. 2017. PMID: 28478383 Review.

2

Harnessing dendritic cells for immunotherapy.

Delamarre L, Mellman I. Delamarre L, et al. Semin Immunol. 2011 Feb;23(1):2-11. doi: 10.1016/j.smim.2011.02.001. Epub 2011 Mar 5. Semin Immunol. 2011. PMID: 21377379 Review.

3

Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation.

Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, Lee WP, Park S, Xu M, DeVoss J, Spooner CJ, Chalouni C, Delamarre L, Mellman I, Singh H. Vander Lugt B, et al. Among authors: delamarre l. Nat Immunol. 2014 Feb;15(2):161-7. doi: 10.1038/ni.2795. Epub 2013 Dec 22. Nat Immunol. 2014. PMID: 24362890

4

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing.

Yadav M, Jhunjhunwala S, Phung QT, Lupardus P, Tanguay J, Bumbaca S, Franci C, Cheung TK, Fritsche J, Weinschenk T, Modrusan Z, Mellman I, Lill JR, Delamarre L. Yadav M, et al. Among authors: delamarre l. Nature. 2014 Nov 27;515(7528):572-6. doi: 10.1038/nature14001. Nature. 2014. PMID: 25428506

5

Cancer immunotherapy. Neo approaches to cancer vaccines.

Delamarre L, Mellman I, Yadav M. Delamarre L, et al. Science. 2015 May 15;348(6236):760-1. doi: 10.1126/science.aab3465. Science. 2015. PMID: 25977539 No abstract available.

6

IMMUNOTHERAPY. Outsourcing the immune response to cancer.

Yadav M, Delamarre L. Yadav M, et al. Among authors: delamarre l. Science. 2016 Jun 10;352(6291):1275-6. doi: 10.1126/science.aag1547. Science. 2016. PMID: 27284181 No abstract available.

7

Building proteomic tool boxes to monitor MHC class I and class II peptides.

Schumacher FR, Delamarre L, Jhunjhunwala S, Modrusan Z, Phung QT, Elias JE, Lill JR. Schumacher FR, et al. Among authors: delamarre l. Proteomics. 2017 Jan;17(1-2). doi: 10.1002/pmic.201600061. Proteomics. 2017. PMID: 27928884 Review.

8

Coexpression of Inhibitory Receptors Enriches for Activated and Functional CD8⁺ T Cells in Murine Syngeneic Tumor Models.

Xiong H, Mittman S, Rodriguez R, Pacheco-Sanchez P, Moskalenko M, Yang Y, Elstrott J, Ritter AT, Müller S, Nickles D, Arenzana TL, Capietto AH, Delamarre L, Modrusan Z, Rutz S, Mellman I, Cubas R. Xiong H, et al. Among authors: delamarre l. Cancer Immunol Res. 2019 Jun;7(6):963-976. doi: 10.1158/2326-6066.CIR-18-0750. Epub 2019 May 7. Cancer Immunol Res. 2019. PMID: 31064777

9

Mutation position is an important determinant for predicting cancer neoantigens.

Capietto AH, Jhunjhunwala S, Pollock SB, Lupardus P, Wong J, Hänsch L, Cevallos J, Chestnut Y, Fernandez A, Lounsbury N, Nozawa T, Singh M, Fan Z, de la Cruz CC, Phung QT, Taraborrelli L, Haley B, Lill JR, Mellman I, Bourgon R, Delamarre L. Capietto AH, et al. Among authors: delamarre l. J Exp Med. 2020 Apr 6;217(4):e20190179. doi: 10.1084/jem.20190179. J Exp Med. 2020. PMID: 31940002 Free PMC article.

10

MAP4K4 negatively regulates CD8 T cell-mediated antitumor and antiviral immunity.

Esen E, Sergin I, Jesudason R, Himmels P, Webster JD, Zhang H, Xu M, Piskol R, McNamara E, Gould S, Capietto AH, Delamarre L, Walsh K, Ye W. Esen E, et al. Among authors: delamarre l. Sci Immunol. 2020 Mar 27;5(45):eaay2245. doi: 10.1126/sciimmunol.aay2245. Sci Immunol. 2020. PMID: 32220977

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

83 results

Search Page

Filters